Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: Double-blind, multicenter, randomized study

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 8, 2001, Pages 2358-2362

  Tarshis, G A ^a   Miskin, B M ^a   Jones, T M ^a   Champlin, J ^a   Wingert, K J ^a   Breen, J D ^a   Brown, M J ^a  

^a Express Care Plus   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; LEVOFLOXACIN;

ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 0034924021     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.8.2358-2362.2001     Document Type: Article

References (27)

1. The macrolides: Erythromycin, clarithromycin, and azithromycin
2. Tolerability of fluoroquinolone antibiotics. Past, present and future
3. Bacterial pathogens isolated from patients with skin and soft tissue infections: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
4. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones
5. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms
6. Antibacterial activity of gatifloxacin (AM-1155, CG4401, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus
7. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections
8. Ofloxacin treatment of difficult infections of the skin and skin structure
9. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: A review of current information on efficacy and safety
10. Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections
11. Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America
12. Ofloxacin, a new broad-spectrum fluoroquinolone. Results of a multicenter, national comparative activity surveillance study
13. Ofloxacin versus cephalexin for treating skin and soft tissue infections
14. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans
15. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections
16. A multicenter, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections
17. Comparative studies of cefprozil in the management of skin and soft-tissue infections
18. Levofloxacin, a second-generation fluoroquinolone
19. Gatifloxacin: ADIS new drug profile
20. Clarithromycin: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential
21. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
22. Impairment of phagocytic cell respiratory burst by UVA in the presence of fluoroquinolones: An oxygen-dependent phototoxic damage to cell surface microvilli
23. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten
24. Cellulitis and subcutaneous tissue infections
25. The management of skin and skin structure infections in children, adolescents and adults: A review of empiric antimicrobial therapy
26. Cefprozil: A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential
27. DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance